-
Leveraging Real-World Data and NLP to Identify At Risk Metabolic Dysfunction Associated Steatohepatitis in the General Population
Mar 27, 2025, 21:39 PM -
The Impact of Hallucinations in Synthetic Health Data on Prognostic Machine Learning Models
Mar 27, 2025, 21:39 PM -
Development and Prospective Evaluation of the Bladder Utility Symptom Scale (Utility): A Novel Tool to Measure Utilities and Quality of LIfe in Bladder Cancer Patients
Mar 27, 2025, 21:39 PM -
Changes in Patient Reported Outcomes Relative to the Time of Disease Progression in Non-Small Cell Lung Cancer
Mar 27, 2025, 21:39 PM -
Patient Reported Adverse Psychosocial Outcomes and Identification of Predictive Factors in Those with Lymphoma or Chronic Lymphocytic Leukemia - An analysis of the Lymphoma Coalition's 2024 Global Patient Survey
Mar 27, 2025, 21:39 PM -
The Landscape of Current Policy and Health Authority Positions on Intermediate Endpoints (IEs) for Clinical Outcomes in Oncology
Mar 27, 2025, 21:39 PM -
Boosting Predictive Power: Thoughtfully Unleashing the Potential of Machine Learning In Real-World Healthcare Outcome Estimation
Mar 27, 2025, 21:39 PM -
Evaluating Fairness Across Machine Learning Algorithms in Health Models Incorporating Race/Ethnicity as Predictors
Mar 27, 2025, 21:39 PM -
Payment Models for Sickle-Cell Disease Gene Therapies in Colorado Medicaid: Real-World Data Analysis
Mar 27, 2025, 21:39 PM -
The Clinical and Financial Benefit of Adopting Negative Pressure Therapy to Reduce Surgical Site Complications after Cesarean Section
Mar 27, 2025, 21:39 PM -
How to Use Real-world Data Across Regions to Gain Regulatory Approval: A Case Study
Mar 27, 2025, 21:39 PM -
Accelerated Access Pathways at Canada’s Drug Agency: Evaluating Progress and Future Directions in HTA
Mar 27, 2025, 21:39 PM -
Navigating Uncertainty Within a Re-evaluation Process: Epidemiological Approach vs Real-World Data in a Budget Impact Analysis for CAR T-cell Therapies in Quebec
Mar 27, 2025, 21:39 PM -
Healthcare Resource Utilization (HCRU) and Cost among Patients with Metastatic Melanoma Receiving Nivolumab + Relatlimab (NIVO+RELA) or Nivolumab + Ipilimumab (NIVO+IPI) in the Optum Database
Mar 27, 2025, 21:39 PM -
Economic Burden of Recurrence among Patients with High-Risk Non-Muscle-Invasive Bladder Cancer who Received Bacillus Calmette-Guérin in the United States: A SEER-Medicare Study
Mar 27, 2025, 21:39 PM -
Long Term Healthcare Costs and Utilization Among Patients with Non Obstructive Hypertrophic Cardiomyopathy
Mar 27, 2025, 21:39 PM -
From Research to Policy: Incorporating Patient Preferences for Colorectal Cancer Treatments Into Health Technology Assessment
Mar 27, 2025, 21:39 PM -
Requirements for Patient-Reported Outcome and Data Analytics in Health Technology Assessment in England, France and Germany, and Opportunities for Methods Harmonization across European Markets
Mar 27, 2025, 21:39 PM -
Inclusion of Health-Related Quality of Life (HRQoL) and Other Patient-Reported Outcomes (PROs) in Reimbursement Reviews From the Canadian Agency for Drugs and Technologies in Health (CADTH)
Mar 27, 2025, 21:39 PM -
A Return On Investment Evaluation Of An Antibiotic Audit And Feedback Program Among Family Physicians
Mar 10, 2025, 14:00 PM
